ArticleBMJ oncology2026

First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours.

Carlos Gomez-Roca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.